Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 347 of 5804
-
Single infusion may prevent chronic headaches after concussion
Disease control Not yet recruitingMost individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH. Patients with migraine-PTH are at greater risk of persistent symptoms whereby the acute PTH (…
Phase: PHASE3 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug cocktail targets hard-to-treat ovarian cancer in early trial
Disease control Recruiting nowThis is a prospective, multicenter, phase II study designed to evaluate the efficacy and safety of disitamab vedotin combined with platinum plus bevacizumab as first-line therapy for HER2-expressing, HRD-negative high-risk ovarian cancer. Forty-three patients with pathologically …
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug combo shows promise in shrinking aggressive stomach tumors before surgery
Disease control Not yet recruitingHER2 overexpression is observed in approximately 20% of gastric cancers and gastroesophageal junction (GEJ) cancers, making it a validated target for anti-tumor therapy . In advanced-stage systemic therapy, trastuzumab combined with chemotherapy has demonstrated clinical benefits…
Phase: PHASE2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Radiation and immunotherapy join forces in new cancer trial
Disease control Not yet recruitingThis prospective randomized trial evaluates the efficacy and safety of combining 125I seed interstitial brachytherapy with immune checkpoint inhibitor therapy in patients with primary, recurrent, or metastatic malignant tumors. Immunotherapy has become an important systemic treat…
Phase: PHASE2 • Sponsor: Li Min • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could a pill replace IV drips for leukemia patients?
Disease control Not yet recruitingLATITUDE: A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2- Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-Hi…
Phase: PHASE3 • Sponsor: SDK Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Could a heart pill help lung cancer patients live longer?
Disease control Not yet recruitingDespite the rapid development of novel anti-cancer therapeutic agents and ensuing improved prognosis, lung cancer remains the leading cause of cancer-related death globally, of which the majority of mortality could be attributed to advanced lung cancer. Hypertension is frequently…
Phase: PHASE2 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Can a pneumonia vaccine protect the most vulnerable children?
⭐️ VACCINE ⭐️ Not yet recruitingThe goal of the OPTIMAL clinical trial is to learn if a dose of a pneumococcal conjugate vaccine (PCV) generates a good immune response in young children who are in hospital with severe acute malnutrition. Researchers will compare an intervention group who get a dose of a PCV (P…
Phase: PHASE4 • Sponsor: Nick Fancourt • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:05 UTC
-
New drug aims to shield kidneys and heart in diabetic patients
Disease control Not yet recruitingTo assess the effect of Finerinone on slowing renal function decline and improving cardiovascular outcomes, particularly heart failure risk, in patients with diabetic CKD.
Phase: NA • Sponsor: College of Physicians and Surgeons Pakistan • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New study aims to outsmart relapse in aggressive blood cancers after transplant
Disease control Not yet recruitingDonor lymphocyte infusion (DLI) based on minimal residual disease (MRD) has been widely adopted worldwide to enhance the graft-versus-leukemia effect following allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, there is a lack of studies comparing the effica…
Phase: NA • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for hard-to-treat breast cancer: combo therapy enters human trials
Disease control Not yet recruitingThis is a multicenter, open-label, Phase Ib/II randomized study designed to evaluate the safety, tolerability, dose-limiting toxicities (DLTs), and preliminary antitumor activity of JSKN016 in combination with the oral selective estrogen receptor degrader (SERD) D-0502 in patient…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Promising new combo therapy for advanced lung cancer enters phase 2 trial
Disease control Recruiting nowThis study will enroll patients with locally advanced non-small cell lung cancer (NSCLC). Patients will receive neoadjuvant chemotherapy combined with dual immune checkpoint blockade (PD-1/CTLA-4), bevacizumab and thymosin alpha 1, followed by concurrent chemoradiotherapy, and fi…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Could early norepinephrine save more septic shock patients?
Disease control Recruiting nowThe goal of this clinical trial is to determine whether early initiation of norepinephrine with rapid dose adjustment improves clinical outcomes in adult patients with septic shock. The study aims to evaluate the effect of early norepinephrine administration on mortality, hemodyn…
Phase: NA • Sponsor: Siriraj Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo targets lung cancer brain tumors in 60-patient trial
Disease control Not yet recruitingThis multicenter study evaluates the efficacy and safety of furmonertinib 160mg versus furmonertinib 80mg plus chemotherapy (carboplatin + pemetrexed) as first-line treatment for EGFR-mutated NSCLC patients with brain metastases. It aims to determine which approach is more effect…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New drug targets Hard-to-Treat heart condition
Disease control Not yet recruitingThis study is a prospective interventional cohort study aimed at evaluating the therapeutic efficacy and clinical utility of Mavacamten-a targeted myosin inhibitor specifically developed for obstructive hypertrophic cardiomyopathy (HCM)-in patients with HCM characterized by mid-t…
Phase: PHASE4 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug duo takes on stubborn Epstein-Barr virus
Disease control Recruiting nowThis study is a multicenter, prospective, single-arm clinical investigation, with patients with CAEBVD as the main research subjects, to evaluate the effectiveness of the combined treatment regimen of golidocitinib and selinexor.
Phase: PHASE2, PHASE3 • Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug could help 'Incompatible' kidney transplants succeed
Disease control Not yet recruitingImlifidase is a recombinant cysteine protease derived from Streptococcus pyogenes and produced in Escherichia coli, which has the ability to cleave and degrade all human IgGs. Four to six hours after imlifidase infusion, the entire IgG pool is degraded into F(ab')2 and Fc fragmen…
Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New stent procedure offers hope for High-Risk aortic tear patients
Disease control Recruiting nowThis study is a single-arm, open-label, multi-center clinical trial evaluating the safety and efficacy of endovascular treatment for retrograde dissection involving the ascending aorta that is not suitable for open surgery. The aim is to assess the short-term (30 days) and medium…
Phase: NA • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Growing new skin in minutes: a breakthrough for chronic wounds?
Disease control Recruiting nowThis multicenter real-world study evaluates the efficacy and safety of a novel technique for rapid intraoperative construction of tissue-engineered skin using autologous epidermal stem cells (EpiSCs) for repairing difficult-to-heal wounds. Eligible patients are randomized to rece…
Phase: NA • Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New combo therapy aims to shrink rectal tumors faster
Disease control Recruiting nowThis study adopts a prospective randomized controlled design to evaluate the efficacy and safety of short-course radiotherapy followed by sequential PD-1 inhibitor and FOLFOX chemotherapy versus conventional regimens in high-risk locally advanced pMMR/MSS lower rectal adenocarcin…
Phase: PHASE2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a floating treadmill and magnetic pulses supercharge stroke recovery?
Disease control CompletedThe goal of this clinical trial is to learn if adding new technologies to standard therapy helps people recover after a stroke. It looks at adults aged 18 to 74 who recently had a stroke and need help with moving and walking. The main questions the study aims to answer are: Doe…
Phase: NA • Sponsor: BTL Industries Ltd. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC